Published on April 29, 2026 by Laurent LAFFERRERE
For a revision of the Micro-Organisms and Toxins (MOT) regulatory framework, more proportionate to risks while maintaining a high level of safety, in line with emerging public health challenges (March 2026)
The French regulatory framework for Micro-Organisms and Toxins (MOT), originally designed in a bioterrorism context, ensures a high level of biosafety but is now misaligned with current research and innovation needs.
Its administrative complexity (multiple authorizations per agent, 4–6 month timelines, heavy traceability requirements) significantly hampers the competitiveness of the French research ecosystem compared to more agile and risk-based European frameworks.
This situation directly impacts the ability to rapidly develop vaccines, diagnostics, and biomedicines, raising concerns for both attractiveness and health resilience.
France BioLead advocates for a shift toward a more proportionate, risk-based regulatory approach, focused on actual risk levels and containment capacities rather than per-agent authorization.
Key recommendations include:
introducing facility-level accreditation schemes;
excluding, under strict scientific criteria, non-reactivable inactivated genetic material;
redefining the notion of “MOT components” based on scientific relevance;
simplifying application requirements and drastically reducing timelines (target: ~10 days to 1 month);
streamlining material transfers, including international exchanges, through modernized procedures.
These measures would align France with best European practices, enhance responsiveness in health crises, and strengthen the competitiveness of the biomanufacturing sector while maintaining a high level of biosafety.
